New research provides evidence that individual differences in dopamine levels in the brain’s putamen region can influence how methylphenidate, a widely used “smart drug,” affects our creative thinking processes. The findings, published in Neuropsychopharmacology, indicate that the use of methylphenidate can impair specific forms of creativity in those with low baseline dopamine levels.